Antibodies and diagnostic tests in antiphosholipid syndrome

[1]  P. Meroni,et al.  Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome , 2019, Front. Immunol..

[2]  S. Baldovino,et al.  Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study , 2019, Front. Immunol..

[3]  M. Petri,et al.  The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. , 2019, Thrombosis research.

[4]  G. Hernández-Molina,et al.  Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome. , 2019, Thrombosis research.

[5]  A. Kirilovsky,et al.  Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria , 2018, Front. Immunol..

[6]  S. Testa,et al.  Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. , 2018, Thrombosis research.

[7]  P. D. de Groot,et al.  New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats , 2018, Haematologica.

[8]  H. Cohen,et al.  Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome. , 2018, Thrombosis research.

[9]  S. Čučnik,et al.  Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements , 2018, Clinical Rheumatology.

[10]  L. Coletto,et al.  Antiphosphatidylserine/prothrombin Antibodies in Antiphospholipid Syndrome with Intrauterine Growth Restriction and Preeclampsia , 2018, The Journal of Rheumatology.

[11]  P. Meroni,et al.  Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications , 2018, Front. Immunol..

[12]  P. Meroni,et al.  Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? , 2018, Nature Reviews Rheumatology.

[13]  A. Tincani,et al.  Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. , 2018, Journal of autoimmunity.

[14]  S. Yasuda,et al.  First‐Line, Non‐Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β2‐Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests , 2018, Arthritis care & research.

[15]  D. Roccatello,et al.  Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis , 2018, Rheumatology.

[16]  Y. Shoenfeld,et al.  Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess , 2018, Lupus.

[17]  A. Vlagea,et al.  IgA anti-β2 glycoprotein I antibodies: Experience from a large center. , 2018, Thrombosis research.

[18]  Mimi Y. Kim,et al.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies , 2018, Annals of the rheumatic diseases.

[19]  D. Roccatello,et al.  Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review , 2017, Seminars in Thrombosis and Hemostasis.

[20]  D. Lora,et al.  Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies , 2017, PloS one.

[21]  H. Yoo,et al.  Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk , 2017, Clinical chemistry and laboratory medicine.

[22]  A. Hoxha,et al.  Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome , 2017, Clinical chemistry and laboratory medicine.

[23]  R. Cervera,et al.  Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study , 2017, Lupus.

[24]  A. Ishizu,et al.  Establishment of a rat model of thrombosis induced by intravenous injection of anti-phosphatidylserine–prothrombin complex antibody , 2017, Rheumatology.

[25]  M. Petri,et al.  Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[26]  P. Meroni.  Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools , 2016, Lupus.

[27]  D. Isenberg,et al.  Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome , 2016, PloS one.

[28]  M. Mahler,et al.  Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers , 2016, Arthritis Research & Therapy.

[29]  D. Lora,et al.  Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events , 2016, Journal of atherosclerosis and thrombosis.

[30]  P. Meroni,et al.  The challenges of lupus anticoagulants , 2016, Expert review of hematology.

[31]  Mimi Y. Kim,et al.  Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results , 2016, Lupus Science & Medicine.

[32]  A. Tincani,et al.  Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2‐Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome , 2015, Arthritis & rheumatology.

[33]  P. Meroni,et al.  Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings? , 2015, The Journal of Rheumatology.

[34]  H. Cohen,et al.  Anti‐protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome , 2014, Journal of thrombosis and haemostasis : JTH.

[35]  A. Tebo.  Antiphospholipid syndrome and the relevance of antibodies to negatively charged phospholipids in diagnostic evaluation , 2014, Lupus.

[36]  M. Petri,et al.  14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. , 2014, Autoimmunity reviews.

[37]  D. Sblattero,et al.  A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. , 2014, Blood.

[38]  G. Elgue,et al.  Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome. , 2014, Thrombosis research.

[39]  P. Meroni,et al.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers , 2014, Arthritis Research & Therapy.

[40]  P. Meroni,et al.  New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies , 2014, Current Rheumatology Reports.

[41]  M. Petri,et al.  Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. , 2013, Arthritis and rheumatism.

[42]  D. Roccatello,et al.  Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome , 2013, Thrombosis and Haemostasis.

[43]  F. Dall’ara,et al.  Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies , 2013, Current Rheumatology Reports.

[44]  A. Hoxha,et al.  Correct laboratory approach to APS diagnosis and monitoring. , 2013, Autoimmunity reviews.

[45]  Y. Shoenfeld,et al.  β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity? , 2012, Autoimmunity reviews.

[46]  V. Pengo,et al.  ISTH guidelines on lupus anticoagulant testing. , 2012, Thrombosis research.

[47]  Masato Nakamura,et al.  A Unique Preliminary Study on Placental Apoptosis in Mice with Passive Immunization of Anti‐Phosphatidylethanolamine Antibodies and Anti‐Factor XII Antibodies , 2011, American journal of reproductive immunology.

[48]  M. Rodger,et al.  The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. , 2011, Thrombosis research.

[49]  P. Meroni,et al.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.

[50]  M. Petri,et al.  ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010 , 2011, Lupus.

[51]  B. Horta,et al.  Association of Anticardiolipin Antibodies With Preeclampsia: A Systematic Review and Meta-Analysis , 2010, Obstetrics and gynecology.

[52]  A. Tincani,et al.  Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? , 2010, Annals of the rheumatic diseases.

[53]  Pojen P. Chen,et al.  Antibodies to Serine Proteases in the Antiphospholipid Syndrome , 2010, Current rheumatology reports.

[54]  P. Vlachoyiannopoulos,et al.  Antithyroid antibodies in antiphospholipid syndrome: prevalence and clinical associations , 2009, Lupus.

[55]  T. Lecompte,et al.  Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system , 2009, Current rheumatology reports.

[56]  Y. Ioannou,et al.  How we diagnose the antiphospholipid syndrome. , 2009, Blood.

[57]  R. Cervera,et al.  Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. , 2008, Autoimmunity reviews.

[58]  Y. Shoenfeld,et al.  Autoantibody explosion in antiphospholipid syndrome. , 2008, Journal of autoimmunity.

[59]  A. Tincani,et al.  Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? , 2008, Journal of autoimmunity.

[60]  S. Andrejević,et al.  Clinical and serological follow-up of 71 patients with anti-mitochondrial type 5 antibodies , 2007, Lupus.

[61]  Pojen P. Chen,et al.  Antibodies against the Activated Coagulation Factor X (FXa) in the Antiphospholipid Syndrome That Interfere with the FXa Inactivation by Antithrombin1 , 2006, The Journal of Immunology.

[62]  S. Kahn,et al.  Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. , 2006, The Journal of rheumatology.

[63]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[64]  R. Perricone,et al.  Anti‐thyroid Antibodies and Antiphospholipid Syndrome: Evidence of Reduced Fecundity and of Poor Pregnancy Outcome in Recurrent Spontaneous Aborters , 2004, American journal of reproductive immunology.

[65]  P. Stevens,et al.  Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. , 2004, Haematologica.

[66]  R. Russo,et al.  Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. , 2004, Blood.

[67]  T. Barbui,et al.  Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. , 2003, Blood.

[68]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[69]  J. Piette,et al.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. , 2002, Arthritis and rheumatism.

[70]  Morabito,et al.  Anti‐mitochondrial M5 type antibody represents one of the serological markers for anti‐phospholipid syndrome distinct from anti‐cardiolipin and anti‐β2‐glycoprotein I antibodies , 1998, Clinical and experimental immunology.

[71]  J. Barker,et al.  Induction of Thrombosis in a Mouse Model by IgG, IgM and IgA Immunoglobulins from Patients with the Antiphospholipid Syndrome , 1995, Thrombosis and Haemostasis.

[72]  W. Barcellini,et al.  Non-Thrombotic Hematologic Manifestations in APS , 2015 .

[73]  S. Testa,et al.  Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. , 2015, Thrombosis research.

[74]  I. Zegers,et al.  Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases , 2014, Nature Reviews Rheumatology.

[75]  P. Meroni,et al.  Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. , 2014, Autoimmunity reviews.

[76]  S. Sciascia,et al.  The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review. , 2013, Autoimmunity reviews.

[77]  M. T. Caleiro,et al.  Clinical and laboratory evaluation of patients with primary antiphospholipid syndrome according to the frequency of antinuclear antibodies (ANA Hep-2). , 2010, Revista brasileira de reumatologia.

[78]  N. Ronda,et al.  Anti-endothelial cell autoantibodies , 2007 .

[79]  A. Tincani,et al.  Immunological Abnormalities in the Antiphospholipid Syndrome , 2002 .